CNS Disease Awareness Campaign Budgeting & Effectiveness

STUDY OVERVIEW
BENCHMARK CLASS
SPECIAL OFFER

Non-members: Click here to review a complimentary excerpt from “Disease Awareness Program Excellence in CNS / Neurology: Budget and Effectiveness”

STUDY OVERVIEW

Given the challenges of diagnosis and treatment in CNS/neurology, awareness programs must be both well-funded and effective in reaching fragmented patient and HCP communities.

This makes understanding the financial planning and outcome measurement of these programs vital for long-term success.

Best Practices, LLC conducted this benchmarking research to examine budget allocation strategies and effectiveness metrics across top CNS-focused disease awareness campaigns. This study provides real-world benchmarks and peer-driven practices that inform better planning and execution.

KEY TOPICS

Neurology Disease Awareness Program Effectiveness
Best Practices and Common Pitfalls
Budget and Spending for CNS Disease Awareness Programs

KEY METRICS

Effectiveness of CNS-focused disease awareness programs
Investment timing across the neurology development-to-launch continuum
CNS disease awareness program budgets: Large vs. mid-small pharma; global vs. country level; single brand vs. portfolio
Peak year CNS / neurology disease awareness investment – Large pharma vs. mid-small pharma
Drivers influencing spend for CNS disease awareness programs on a product-by-product basis – Total benchmark class, large vs. mid-small pharma; single brand vs. portfolio
Funding sources supporting CNS-focused disease education
Disease awareness investment for new CNS treatments addressing unmet clinical needs

SAMPLE KEY FINDINGS

Budget and Funding: Launch year and launch -1 year are the peak periods for disease awareness spending.

METHODOLOGY

Best Practices, LLC conducted this benchmarking research by engaging 9 leaders from 9 life sciences organizations specializing in CNS therapies. In addition to quantitative input, several participants shared deeper operational perspectives through one-on-one interviews. Relevant secondary research is incorporated to provide additional context.

Industries Profiled:
Pharmaceutical; Biotech; Manufacturing; Biopharmaceutical; Public Relations; Chemical; Health Care; Communications

Companies Profiled:
Adamas Pharmaceuticals; Biogen; Catalyst Pharmaceuticals; FleishmanHillard; Genentech; Genzyme; Indivior; Merck KGaA; NexGen Healthcare

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.

Disease Awareness Program Excellence in CNS / Neurology: Budget and Effectiveness

ID: 5870

Features:

Pages/Slides: 25

Published: 2025

Delivery Format: Online PDF Document

RELATED RESEARCH

1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6AA528F812362199100258C77003CB62B
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-disease-awareness-program-cns-neurology-budget-effectiveness?opendocument
18
19opendocument
2018.97.14.81
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB